GAM
NVCR icon

Grandview Asset Management’s NovoCure NVCR Stock Holding History

Grandview Asset Management’s Portfolio NVCR Stock Details NVCR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-174
Closed -$23K – 332
2021
Q1 		$23K Buy
+174
New +$27.5K 0.01% 270

Other funds holding NVCR

Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
CS
Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Grandview Asset Management's NVCR Position: Q2 2021 in Review

Grandview Asset Management sold out of NovoCure (NVCR) in Q2 2021, closing a stake of 174 shares — an estimated $23K sold.

Grandview Asset Management first reported a position in NVCR in Q1 2021 and held it in 1 quarter. The position peaked at $23K in Q1 2021. 361 funds tracked by Wall St. Rank hold NVCR as of Q2 2021.

  • Grandview Asset Management reported no remaining NovoCure position as of Q2 2021 after selling out during the quarter.
  • Grandview Asset Management sold 174 NovoCure shares in Q2 2021, an estimated $23K.
  • Grandview Asset Management first reported a position in NovoCure in Q1 2021 and held it in 1 quarter.
  • Grandview Asset Management's NovoCure position peaked at $23K in Q1 2021.
  • 361 funds tracked by Wall St. Rank held NovoCure as of Q2 2021.

Based on Grandview Asset Management's 13F filing for Q2 2021, filed 21 Jul 2021.